News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
April 2016
-
Media ReleaseNew analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapyThe analysis determined that Entresto benefited patients considered clinically stable, with no history or only a remote history of prior heart failure hospitalization, just as much as it did those…
-
Media ReleaseNew analyses show Novartis' Entresto™ reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction (HFrEF) regardless of prior heart failure hospital admissions or background therapy
March 2016
-
Media ReleaseNew Novartis data show Cosentyx demonstrated sustained superiority in skin clearance (PASI 90) versus Stelara at Week 52- Late-breaking data at AAD show Cosentyx® remains superior to Stelara® in achieving almost clear skin (PASI 90) at Week 16 and at one year in 76.2% versus 60.6% of moderate to severe psoriasis…
-
Media ReleaseNew Novartis data show Cosentyx demonstrated sustained superiority in skin clearance (PASI 90) versus Stelara at Week 52
February 2016
-
Media ReleaseFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NETApproval helps fulfill unmet need as progressive,…
-
Media ReleaseFDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
January 2016
-
Media ReleaseNovartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis- Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)- Approvals for both indications…
-
Media ReleaseNovartis receives two new FDA approvals for Cosentyx® (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
December 2015
-
Media ReleaseNovartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis- Cosentyx (secukinumab) is the first IL-17A antagonist to complete Phase III studies which demonstrated efficacy and assessed safety in ankylosing spondylitis (AS)(1)- Cosentyx provided improvements…
-
Media ReleaseNovartis announces publication of two landmark studies in NEJM demonstrating efficacy of Cosentyx® in patients with ankylosing spondylitis
-
Media ReleaseNovartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL- 55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults [1]- Additional data presented include analyses on…
-
Media ReleaseNovartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
Pagination
- ‹ Previous page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- …
- 56
- › Next page